Jessica Walters

Cobenfy gains NMPA approval in China, offering a groundbreaking treatment for schizophrenia with a unique mechanism and improved symptom management.

Vistagen's fasedienol fails to show significant efficacy in treating social anxiety disorder, despite favorable safety data from the PALISADE-3 trial.

Discover new research on schizophrenia treatments, including digital therapeutics and valbenazine, showcasing significant improvements in patient outcomes.

Roche reveals promising results for trontinemab, an Alzheimer antibody, showing significant amyloid plaque reduction in patients during ongoing trials.

A groundbreaking at-home brain stimulation device gains FDA approval, offering hope for adults with major depressive disorder through innovative treatment.

New research suggests semaglutide may protect against lithium-induced renal injury, offering hope for safer bipolar disorder treatments.

Recent trials reveal oral semaglutide fails to improve cognition or function in early Alzheimer disease, raising questions about its efficacy.

Merck presents promising Phase 1 trial results for MK-2214, a novel Alzheimer treatment, showcasing its potential to slow disease progression.

A recent survey reveals that 13% of US youth use generative AI for mental health advice, highlighting its perceived benefits and potential risks.

New neuroimaging data reveals XPro1595's potential to combat neuroinflammation in early Alzheimer’s disease, offering hope for slowing progression.

Explore updates from November 2025, including AI, drug updates, and more.

Tiffani Bell-Washington, MD, MPH shares insights on compassionate lifestyle changes for adolescents facing obesity, emphasizing collaboration and individualized care strategies.

Otsuka Pharmaceutical submits a new drug application for centanafadine for treatment of ADHD, showing significant efficacy across all age groups.

Hormonal fluctuations significantly influence ADHD symptoms in women, highlighting the need for tailored treatments and further research in this area.

Experts discuss the advantages of long-acting injectables in schizophrenia treatment, highlighting improved adherence, reduced relapse risk, and better patient outcomes.

Lipocine's LPCN 1154 shows promise in treating postpartum depression, with a favorable safety profile and potential for rapid relief.

Explore the unique benefits of Ingrezza, a VMAT2 inhibitor for tardive dyskinesia, and how it compares to other treatment options.

At-home transcranial magnetic stimulation offers a safe, effective way to treat depression, enhancing access and reducing reliance on medications.

Tonmya, a groundbreaking fibromyalgia treatment, is now available in the US, offering hope for millions suffering from chronic pain.

New analysis reveals that negative symptoms and stimulant use may predict positive responses to Cobenfy in schizophrenia treatment.

Iclepertin shows no significant cognitive improvement in schizophrenia patients despite good tolerability, highlighting challenges in treating cognitive impairment.

FDA committee discusses potential and risks of AI-enabled digital mental health devices.

A recent study links lower income to higher dementia risk factors, highlighting the need for targeted interventions in vulnerable populations.

New phase 4 data reveals Austedo significantly reduces involuntary movements and enhances quality of life for adults with tardive dyskinesia.

Psyence BioMed phase 2b trial explores psilocybin therapy for adjustment disorder in palliative care, aiming for groundbreaking treatment advancements.

FDA approves Caplyta for major depressive disorder, a new sNDA for Alzheimer disease, and news in correctional psychiatry.

Nutriband engages with the FDA on its innovative abuse-deterrent fentanyl patch, paving the way for safer pain management solutions.